Contributions
Abstract: P485
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 17 Environmental factors
Introduction: Vitamin D deficiency is a risk factor for multiple sclerosis (MS). Low vitamin D levels are associated with increased risk of brain lesions, relapses and early progression of disability. Vitamin D levels have been associated with disease activity mainly in relapsing remitting and to a lesser extent in progressive forms of the disease.
Objectives: To examine the association between vitamin D levels and MRI features in progressive multiple sclerosis subjects (primary progressive [PPMS] and secondary progressive [SPMS]) from the ibudilast phase II clinical trial (NN201/SPRINT-MS).
Methods: 25 OH vitamin D levels (D3 and total D) were conducted on baseline serum samples from the subjects enrolled into the NN102/SPRINT-MS trial. Clinical and disease data included demographics, disease history, Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC), T2 lesion volume, T1 lesion volume, brain parenchymal fraction (BPF), whole brain MTR (WBMTR), normal appearing brain tissue MTR (NABT MTR), and normal appearing grey matter MTR (NAGM MTR). Associations between vitamin D levels and MS features were determined using Pearson correlation and multivariate regression analyses.
Results: The sample included 267 patients (Age 55.6±7.4, 47.2% male, and 51.3% PPMS) who had both baseline key MRI data and vitamin D levels. No difference between PPMS and SPMS was found for mean D3 (40.7 vs. 39.9 ng/ml) and total D (43.8 vs. 42.9 ng/ml). Positive associations were found between D3 and MRI measures including WBMTR (r=0.17, p=0.007), NABT MTR (r=0.12, p=0.07) and NAGM MTR (r=0.15, p=0.02), but the associations with total D was not significant. There was no significant association between D3 or total D and other MRI measures including BPF, T2 lesion volume, T1 lesion volumes, or clinical measures. Associations between vitamin D3 level and WB MTR reminded significant (p=0.02) in multivariate analysis with consideration of age, gender, disease duration, time of serum obtained and latitude of study site. Every 10 ng/ml increase in vitamin D3 resulted in a 2.1 percent unit increase in WB MTR.
Conclusions: Vitamin D levels were significantly associated with whole brain MTR, but not with BPF, T2 lesion volume, T1 lesion volume, or clinical measures in progressive MS. Vitamin D may carry a protective role in myelin content in progressive MS patients.
Disclosure:
Supported by NINDS (U01NS082329; U01NS077179, U01NS077352) and NMSS (RG 4778-A-6 and PP-1603-08307)
DO Grant support from Genzyme, Genentech, Novartis, consulting from Biogen Idec and Genentech
JA: nothing to disclose
HL: nothing to disclose
RJF: Consulting fees from Actelion, Biogen, Genentech, Novartis, and Teva. Advisory committees for Biogen Idec and Novartis. Clinical trial contract and research grant funding from Biogen and Novartis.
Abstract: P485
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - 17 Environmental factors
Introduction: Vitamin D deficiency is a risk factor for multiple sclerosis (MS). Low vitamin D levels are associated with increased risk of brain lesions, relapses and early progression of disability. Vitamin D levels have been associated with disease activity mainly in relapsing remitting and to a lesser extent in progressive forms of the disease.
Objectives: To examine the association between vitamin D levels and MRI features in progressive multiple sclerosis subjects (primary progressive [PPMS] and secondary progressive [SPMS]) from the ibudilast phase II clinical trial (NN201/SPRINT-MS).
Methods: 25 OH vitamin D levels (D3 and total D) were conducted on baseline serum samples from the subjects enrolled into the NN102/SPRINT-MS trial. Clinical and disease data included demographics, disease history, Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC), T2 lesion volume, T1 lesion volume, brain parenchymal fraction (BPF), whole brain MTR (WBMTR), normal appearing brain tissue MTR (NABT MTR), and normal appearing grey matter MTR (NAGM MTR). Associations between vitamin D levels and MS features were determined using Pearson correlation and multivariate regression analyses.
Results: The sample included 267 patients (Age 55.6±7.4, 47.2% male, and 51.3% PPMS) who had both baseline key MRI data and vitamin D levels. No difference between PPMS and SPMS was found for mean D3 (40.7 vs. 39.9 ng/ml) and total D (43.8 vs. 42.9 ng/ml). Positive associations were found between D3 and MRI measures including WBMTR (r=0.17, p=0.007), NABT MTR (r=0.12, p=0.07) and NAGM MTR (r=0.15, p=0.02), but the associations with total D was not significant. There was no significant association between D3 or total D and other MRI measures including BPF, T2 lesion volume, T1 lesion volumes, or clinical measures. Associations between vitamin D3 level and WB MTR reminded significant (p=0.02) in multivariate analysis with consideration of age, gender, disease duration, time of serum obtained and latitude of study site. Every 10 ng/ml increase in vitamin D3 resulted in a 2.1 percent unit increase in WB MTR.
Conclusions: Vitamin D levels were significantly associated with whole brain MTR, but not with BPF, T2 lesion volume, T1 lesion volume, or clinical measures in progressive MS. Vitamin D may carry a protective role in myelin content in progressive MS patients.
Disclosure:
Supported by NINDS (U01NS082329; U01NS077179, U01NS077352) and NMSS (RG 4778-A-6 and PP-1603-08307)
DO Grant support from Genzyme, Genentech, Novartis, consulting from Biogen Idec and Genentech
JA: nothing to disclose
HL: nothing to disclose
RJF: Consulting fees from Actelion, Biogen, Genentech, Novartis, and Teva. Advisory committees for Biogen Idec and Novartis. Clinical trial contract and research grant funding from Biogen and Novartis.